Related Experiment Video
Updated: Aug 14, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
New treatment strategies for malignant gliomas
N G Avgeropoulos1, T T Batchelor
1Brain Tumor Center, Massachusetts General Hospital, Boston 02114, USA.
Abstract:
Although survival in patients with malignant gliomas remains limited, there is renewed optimism with the emergence of novel treatment strategies. Cytotoxic agents such as temozolomide and CPT-11 have shown promising clinical activity. Biological treatments for brain tumors, including antisense oligonucleotides, gene therapy, and angiogenesis inhibitors, are also being evaluated in clinical trials. Delivery strategies have been developed to overcome challenges presented by the blood-brain barrier. These noteworthy treatments, alone or in combination, may ultimately prolong survival and enhance quality of life in this group of patients.
Insights
Novel treatments for malignant gliomas, including cytotoxic agents and biological therapies, offer new hope. These strategies, alongside improved delivery methods, aim to extend survival and improve quality of life for patients.
Area of Science:
- Neuro-oncology
- Cancer Therapeutics
- Pharmacology
Background:
- Malignant gliomas have a poor prognosis, necessitating innovative treatment approaches.
- Existing treatments face challenges, including the blood-brain barrier.
- Recent advancements offer renewed optimism for managing these brain tumors.
Purpose of the Study:
- To review emerging novel treatment strategies for malignant gliomas.
- To highlight advancements in drug delivery for brain tumors.
- To discuss the potential impact of these treatments on patient survival and quality of life.
Main Methods:
- Review of current cytotoxic agents (e.g., temozolomide, CPT-11).
- Evaluation of biological treatments under investigation (e.g., gene therapy, angiogenesis inhibitors).
- Discussion of strategies to overcome the blood-brain barrier.
Main Results:
- Temozolomide and CPT-11 demonstrate promising clinical activity.
- Various biological therapies are progressing through clinical trials.
- Development of advanced delivery systems enhances therapeutic potential.
Conclusions:
- Novel cytotoxic and biological treatments hold significant promise for malignant glioma patients.
- Effective delivery strategies are crucial for overcoming the blood-brain barrier.
- Combination therapies may ultimately improve survival and quality of life.
